



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 81344

Title: Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02938533

Position: Editorial Board

Academic degree: PhD

Professional title: Associate Professor, Pharmacist, Senior Scientist

Reviewer's Country/Territory: Egypt

Author's Country/Territory: China

Manuscript submission date: 2022-11-04

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-11-22 10:30

Reviewer performed review: 2022-11-24 09:43

Review time: 1 Day and 23 Hours

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The authors are showing a case report about a patient who achieved bladder preservation and has been tumor-free for more than two years upon receiving a combination of chemotherapy (cisplatin/gemcitabine) and immunotherapy (tislelizumab) treatment. The manuscript is very well written and the case is clearly and sufficiently presented. I highly recommend this paper for publication as it opens a highly channel for the application of combined chemo/immuno therapy that many basic and translational research studies have been recommending for many years. It provides a real-world evidence that needs to be further applied and confirmed by stronger and wider studies. The manuscript requires English revision.



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 81344

Title: Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05630677

Position: Editorial Board

Academic degree: PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: Iran

Author's Country/Territory: China

Manuscript submission date: 2022-11-04

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-12-02 14:36

Reviewer performed review: 2022-12-02 14:45

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input type="checkbox"/>] Anonymous [<input checked="" type="checkbox"/>] Onymous
	Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No

SPECIFIC COMMENTS TO AUTHORS

Yang R et al. reported a case of programmed cell death-ligand 1 (PD-L1) expression positive MIBC with squamous and glandular differentiation, who refused total cystectomy. The patient received combination treatment with chemotherapy and immunotherapy after successful transurethral resection of the bladder tumor (TURBT). A marked response to combination treatment was achieved and the patient successfully preserved bladder function. Not only the case is presented thoroughly, the article is also written in good scientific and English style and could be published in its current format. However, I would like to suggest listing the NGS results and the mutated genes in a Table and compare those findings in a more comprehensive way in the discussion.